---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-116632"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2026-10-16T20:30:35+00:00"
generated_at: "2026-10-16T20:32:03.440220+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acurx holders re-elect Luci, Dean as Class II directors; ratify CohnReznick for FY2026

## Summary
- Annual meeting held Oct 16, 2026; record date Aug 20, 2026 with 5,471,297 shares outstanding; quorum of 2,890,899 shares, or 52.83%.
- David P. Luci re-elected with 1,187,323 votes for and 73,804 withheld; Jack H. Dean with 1,203,310 for and 57,817 withheld.
- Both Class II directors serve three-year terms expiring in 2029; broker non-votes totaled 1,629,772 on the director proposals.
- Stockholders ratified CohnReznick LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2026: 2,877,193 for, 8,473 against, 5,233 abstentions.
- Two proposals were submitted, per the definitive proxy statement filed Sept 1, 2026; no other business reported.

## SEC filing metadata
- accession: 0001104659-26-116632
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2026-10-16T20:30:35+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465926116632/0001104659-26-116632-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465926116632/tm2627481d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-116632
- JSON: https://secwatch.observer/filing/0001104659-26-116632.json
- Plain text: https://secwatch.observer/filing/0001104659-26-116632.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.